Overview and Scope
Allogeneic cell therapy is a treatment in which cells are harvested from a donor and used to treat a different individual (the recipient). These therapies are designed to replace or repair damaged tissues, modulate immune responses, or treat diseases such as cancer, genetic disorders, and autoimmune conditions.
Sizing and Forecast
The allogenic cell therapy market size has grown rapidly in recent years. It will grow from $0.97 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to an increased focus on tailoring donor cell selection and genetic modifications, increased population, increase in the global burden of chronic diseases, increased awareness, and increase in the number of collaborations for biosimilar development.
The allogenic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the increasing need for advanced medical treatments, growing demand for novel allogeneic cell therapies, rising number of clinical trials, growing patient population contributions, and rising income levels. Major trends in the forecast period include technology advancements, partnerships, big companies collaborating with others, merger and acquisitions, new product launch.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Segmentation & Regional Insights
The allogeneic cell therapy market covered in this report is segmented –
1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders, Other Therapeutic Area
3) By End User: Hospitals, Specialty Clinics, Research Organizations
North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15976&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of chronic diseases is expected to drive the growth of the allogeneic cell therapy market. Chronic disease is a long-lasting condition that typically requires ongoing medical attention and can limit daily activities or quality of life. The prevalence of chronic disease is due to altered habits, inheritance, and exposure to chemicals, toxins, and pollutants in the air. Allogeneic cell therapy holds significant potential for treating a wide range of chronic diseases by utilizing healthy cells from a donor to repair, replace, or modulate the dysfunctional cells or tissues in the recipient. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based medicine library, the number of people aged 50 and above who suffer from one or more chronic illnesses is expected to increase by 99.5% by 2050, from 71.52 million in 2020 to 142.66 million. Therefore, the increased prevalence of chronic diseases drives the growth of the allogeneic cell therapy market.
Key Industry Players
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG
The allogeneic cell therapy market report table of contents includes:
1. Executive Summary
2. Allogeneic Cell Therapy Market Characteristics
3. Allogeneic Cell Therapy Market Trends And Strategies
4. Allogeneic Cell Therapy Market – Macro Economic Scenario
5. Global Allogeneic Cell Therapy Market Size and Growth
.
.
.
32. Global Allogeneic Cell Therapy Market Competitive Benchmarking
33. Global Allogeneic Cell Therapy Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Allogeneic Cell Therapy Market
35. Allogeneic Cell Therapy Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
